Skip to content
Catalyst

PapersPMID:42192187

Effects of Coenzyme Q10 on Lipid, Glycemic, and Inflammatory Markers in Metabolic Disorders: A Systematic Review and Meta-Analysis.

Journal of diabetes research2026The record ↗

findings
11
compound
1
endpoints
11
no difference found
2
PMID:42192187
  1. Finding, moderate evidencelowersInterleukin-6 concentration
  2. Finding, moderate evidencelowersFasting blood glucose
  3. Finding, moderate evidencelowersHOMA-IR
  4. Finding, moderate evidencelowersTumour necrosis factor alpha concentration
  5. Finding, limited evidencelowersGlycated haemoglobin (HbA1c)
  6. Finding, limited evidencelowersTriglycerides
  7. Finding, limited evidencelowersTotal cholesterol (TC)
  8. Finding, limited evidenceraisesHDL cholesterol
  9. Finding, limited evidencelowersLDL cholesterol
  10. Finding, moderate evidenceno difference foundSerum adiponectin
  11. Finding, limited evidenceno difference foundSerum leptin
Study, every finding
meta-analysis

What moved

How to read these marks →
  • Decreases interleukin-6 concentration

    moderatereplicated ×2

    “The pooled analysis indicated that CoQ10 supplementation significantly reduced IL‐6 levels (SMD = −0.42; 95% CI: −0.79, −0.05; I 2 = 74.0 %; p < 0.001).”
    Effect
    −0.42 standardised mean difference, 95% CI −0.79 to −0.05
    Dose studied
    CoQ10 60 to 600 mg/day, pooled; 4 to 24 weeks
    Population
    Adults with disorders of lipid and/or glucose metabolism; ten randomised trials pooled, CoQ10 alone or with co-interventions against a control receiving the same co-intervention
  • Decreases fasting blood glucose

    moderatereplicated ×2

    “Pooled analysis showed that CoQ10 supplementation significantly reduced fasting glucose, with substantial heterogeneity (WMD = −10.07 mg/dL; 95% CI: −14.75, −5.39; I 2 = 87.6 %; p < 0.001).”
    Effect
    −10.07 mean difference, 95% CI −14.75 to −5.39
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Decreases HOMA-IR

    moderate

    “A meta‐analysis of 11 trial arms (324 participants in the CoQ10 groups and 325 in the control groups) showed that CoQ10 supplementation significantly reduced HOMA‐IR (WMD = −0.82; 95% CI: −1.36, −0.28; I 2 = 90.0 %; p < 0.001).”
    Effect
    −0.82 mean difference, 95% CI −1.36 to −0.28
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Decreases tumour necrosis factor alpha concentration

    moderatereplicated ×3

    “Pooled analysis of five RCTs (100 participants in the CoQ10 groups and 94 in the control groups) showed that CoQ10 supplement significantly reduced TNF‐ α levels (SMD = −1.01; 95% CI: −1.56, −0.46; I 2 = 68.6 %; p = 0.013).”
    Effect
    −1.01 standardised mean difference, 95% CI −1.56 to −0.46
    Dose studied
    CoQ10 60 to 600 mg/day, pooled; 4 to 24 weeks
    Population
    Adults with disorders of lipid and/or glucose metabolism; five randomised trials pooled, CoQ10 alone or with co-interventions against a control receiving the same co-intervention
  • Decreases glycated haemoglobin (HbA1c)

    limited

    “Based on 31 trial arms (752 participants in the CoQ10 groups and 751 in the control groups), CoQ10 supplementation was associated with a significant reduction in HbA1c (WMD = −0.22 %; 95% CI: −0.37, −0.06; I 2 = 67.2 %; p < 0.001).”
    Effect
    −0.22 mean difference, 95% CI −0.37 to −0.06
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Decreases triglycerides

    limited

    “Forty‐two trial arms (933 participants in the CoQ10 groups and 928 in the control groups) showed that CoQ10 supplementation significantly reduced serum TG, with low‐to‐moderate heterogeneity.”
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Decreases total cholesterol (TC)

    limited

    “Forty‐eight trial arms (1063 participants in the CoQ10 groups and 1052 in the control groups) showed that CoQ10 supplementation significantly reduced serum TC (WMD = −4.86 mg/dL; 95% CI: −8.41, −1.30).”
    Effect
    −4.86 mean difference, 95% CI −8.41 to −1.3
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Increases HDL cholesterol

    limited

    “Across 48 trial arms (1070 participants receiving CoQ10 and 1058 controls), CoQ10 supplementation was associated with a significant increase in HDL‐C (WMD = 1.07 mg/dL; 95% CI: 0.22, 1.92).”
    Effect
    1.07 mean difference, 95% CI 0.22 to 1.92
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10
  • Decreases LDL cholesterol

    limited

    “Pooled results revealed that the CoQ10 supplement significantly reduced LDL‐C concentrations (WMD = −3.98 mg/dL; 95% CI: −7.00, −0.97; I 2 = 78.1 %; p < 0.001).”
    Effect
    −3.98 mean difference, 95% CI −7 to −0.97
    Dose studied
    60 to 600 mg/day, pooled
    Population
    Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10

What did not

  • “The pooled estimates showed no significant effect of CoQ10 on adiponectin (WMD = 1.37 μg/mL; 95% CI: −0.35, 3.27; I 2 = 65.9 %; p = 0.032) or leptin (SMD = −0.32; 95% CI: −0.70, 0.06; I 2 = 0.0 %; p = 0.872), as both CIs crossed the null.”
    • No detected effect on serum adiponectin

      moderate

      Effect
      1.37 mean difference, 95% CI −0.35 to 3.27
      Dose studied
      60 to 600 mg/day, pooled
      Population
      Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10 (four RCTs)
    • No detected effect on serum leptin

      limited

      Effect
      −0.32 standardised mean difference, 95% CI −0.7 to 0.06
      Dose studied
      60 to 600 mg/day, pooled
      Population
      Adults with disorders of lipid and/or glucose metabolism, pooled randomized trials of CoQ10 alone or with co-interventions, against placebo, no treatment or the same co-intervention without CoQ10 (two RCTs)

Study record

Design
meta-analysis
Species
human
Population
Adults with disorders of lipid and/or glucose metabolism in 64 randomized trials (dyslipidemia, diabetes or IGT, PCOS, CAD, metabolic syndrome, NAFLD); most trials used ubiquinone, two used ubiquinol
Participants
3,422
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
26